Alloksys announces first patients enrolled in the continuation of the APPIRED III clinical trial with RESCAP® in patients undergoing cardiothoracic surgery
October 1, 2024. Alloksys anticipates that in the just started continuation of the APPIRED III study (a placebo-controlled combined phase IIb / III trial), with